Hormuz Crisis: Middle East Conflict Strains Asia’s Medical Device Manufacturing

The precision of modern medicine often relies on a fragile, invisible web of global logistics. For many, the conflict in the Middle East feels like a distant geopolitical struggle, but for healthcare providers and patients across Asia, the consequences are becoming physical. As the blockade of the Strait of Hormuz persists, Asia’s medical device manufacturing strained amid Strait of Hormuz crisis is no longer a theoretical risk—We see a mounting clinical reality.

The catalyst for this instability was the launch of Operation Epic Fury on February 28, 2026, when the United States and partner forces targeted Iranian leadership and nuclear-related sites according to legal and restructuring updates. While the immediate focus was on military and nuclear objectives, the commercial fallout has been swift. The Strait of Hormuz, a critical chokepoint through which roughly 25% of global oil trade and 20% of global LNG trade flow, has seen severe disruptions per current market analysis. For the medical world, the most alarming disruption isn’t just fuel—it is naphtha.

As a physician, I have seen how a shortage of a single component can paralyze a hospital ward. Naphtha is the unsung hero of the medical supply chain; it is a primary petrochemical feedstock used to create the high-grade plastics—such as polyethylene and polypropylene—essential for everything from sterile syringes and catheters to complex surgical tubing. When the flow of naphtha from the Middle East is throttled, the production of these basic, life-saving tools begins to falter.

The Petrochemical Pipeline: Why Naphtha Shortages Matter

To understand why a maritime blockade in the Persian Gulf leads to a shortage of medical plastics in Asia, one must appear at the chemistry of production. Naphtha is derived from crude oil and serves as the foundational building block for ethylene, and propylene. These chemicals are then polymerized into the plastics that define modern sterile healthcare. Without a steady supply of naphtha, manufacturers cannot maintain the volume of medical-grade resins required for mass production.

The current conflict has severely constrained these supplies. Reports indicate that Asian petrochemical producers, who rely heavily on Middle Eastern crude, are facing acute disruptions. This has led to a surge in raw material costs, which are inevitably passed down the chain. In some regions, manufacturers are anticipating price increases of up to 50% for key plastic feedstocks, a cost that may eventually reach the patient or the healthcare system.

Regional Fallout: From Tokyo to Seoul

The impact is not uniform, but it is widespread. Different Asian economies are feeling the strain based on their specific reliance on the Strait of Hormuz for their energy and chemical needs.

In Japan, the situation is particularly precarious. Reports suggest that over 40% of Japan’s naphtha imports originate in the Middle East. This dependency has forced several petrochemical firms—including Mitsui Chemical and Maruzen Petrochemical—to cancel import tenders and announce production cuts. It is reported that at least six of the nation’s 12 ethylene production facilities are reducing output to manage the shortage. Companies like Tosoh Corp. And Shin-Etsu Chemical have reportedly increased prices for polyethylene and polyvinyl chloride resin.

South Korea, as Asia’s largest importer of Middle Eastern naphtha, faces an even steeper challenge, sourcing approximately 54% of its supply through the Strait of Hormuz. The South Korean government has reportedly intervened, implementing emergency measures to restrict naphtha exports from domestic oil refiners to ensure that internal production doesn’t collapse entirely. Major producers such as LG Chem, SK Energy, GS Caltex, and Lotte Chemical are now under pressure to find alternative sources or implement significant output cuts.

In Southeast Asia, the strain is equally evident. In Singapore, where naphtha is critical for the production of catheters and syringes, firms like Aster Chemicals and Energy and PCS have reportedly declared “force majeure” on shipments. Similarly, Indonesia’s Chandra Asri has reportedly declared force majeure on all contracts, citing the inability to secure raw materials due to the Middle East conflict.

Beyond Plastics: Helium, Logistics, and the Cost of Care

While the naphtha crisis dominates the headlines, We find other “silent” risks emerging from the conflict that could jeopardize diagnostic capabilities. One such risk is the global supply of helium. Qatar is the world’s second-largest producer of helium, a gas that is indispensable for cooling the superconducting magnets in MRI machines. With roughly 50,000 MRI machines in apply worldwide, a prolonged disruption in Qatari exports could lead to soaring procurement costs and potential downtime for critical imaging services.

the physical movement of medical goods has become prohibitively expensive. The war has disrupted major logistics corridors and Gulf air hubs, leading to global shipping delays. The financial burden is most evident in marine insurance; war coverage for vessels in the Strait of Hormuz has reportedly risen by over 1,000%, while Red Sea route coverage has nearly doubled. These overheads increase the cost of every component that must cross these waters.

The human cost is already appearing in the most vulnerable regions. While hubs like Singapore maintain stockpiles, the World Health Organization (WHO) has reported deficits in vulnerable nations, particularly in Africa. The WHO’s Dubai hub has reportedly paused operations amid airspace disruptions, further complicating the delivery of emergency medical supplies to those who can least afford a delay.

Adapting to a New Normal: “Just-in-Case” Manufacturing

For decades, the global medical device industry operated on a “just-in-time” (JIT) model—minimizing inventory to reduce costs and relying on a seamless global flow of materials. The current crisis has exposed the fragility of this approach. We are now seeing a strategic pivot toward “just-in-case” (JIC) supply chain management.

Manufacturers are now prioritizing resilience over efficiency by:

• Building Buffer Stocks: Increasing the volume of raw materials held on-site to weather short-term blockades.
• Diversifying Suppliers: Seeking secondary sources of naphtha and plastics outside of the Middle East to reduce geographic dependency.
• Relocating Production: Some Chinese enterprises are reportedly relocating production capacity to Europe, the Middle East, or other parts of Southeast Asia to bring manufacturing closer to alternative raw material sources.
• R&D Investment: Increasing investment into alternative materials that do not rely on naphtha-based petrochemicals.

While these shifts are necessary, they are long-term structural changes. They do not solve the immediate shortage of syringes in a clinic or the rising cost of a catheter today. The transition to a more resilient healthcare supply chain is a marathon, but the current crisis is a sprint that many manufacturers are struggling to run.

Key Takeaways: The Health Impact of the Hormuz Crisis

The current situation underscores a vital lesson: health security is inseparable from energy and maritime security. When a chokepoint like the Strait of Hormuz is closed, the impact travels from the oil tanker to the petrochemical plant, and finally to the patient’s bedside.

As we look forward, the global energy market is entering a period of deep uncertainty according to policy experts. Governments and industry leaders are now forced to trade off short-term relief against long-term energy security and supply diversification. The next critical checkpoint will be the upcoming reviews of national energy policies in Asia and Europe, which will determine how these regions decouple their essential healthcare infrastructure from volatile geopolitical zones.

Do you suppose healthcare systems should mandate national stockpiles of raw medical materials to prevent these crises? Share your thoughts in the comments below or share this article with your colleagues in the medical community.